Ixamet M 50/500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the incretin system, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and improving peripheral insulin sensitivity. The synergistic effect of these two agents helps achieve better glycemic control by targeting different pathophysiological defects of type 2 diabetes. Ixamet M is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled on monotherapy or when dual therapy is deemed appropriate. It is important to monitor renal function prior to initiation and periodically during treatment due to the risk of lactic acidosis associated with Metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Dose adjustments may be necessary in patients with renal impairment or other comorbid conditions. Ixamet M should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes.